Is CorMedix, Inc. overvalued or undervalued?

As of 7 August 2025, the valuation grade for CorMedix, Inc. has moved from expensive to very attractive, indicating a significant improvement in its perceived value. The company appears to be undervalued, especially given its PEG ratio of 0.42, which suggests strong growth potential relative to its price. Additionally, the P/E ratio stands at 55, while the EV to EBITDA ratio is 57.92, both of which are high but may reflect the company's growth prospects in the pharmaceuticals and biotechnology sector.
In comparison to its peer, Xeris Biopharma Holdings, Inc., which has a P/E ratio of -38.70 and an EV to EBITDA of 517.94, CorMedix shows a more favorable valuation profile. The company's ROCE of 38.54% and ROE of 14.95% further support the notion of its strong operational efficiency. While CorMedix has faced recent stock declines, with a 1-week return of -10.70% compared to a 1.05% gain in the S&P 500, its year-to-date return of 44.32% significantly outpaces the index's 12.22%, reinforcing its attractiveness as a potential investment.